#WCLC25: Merck and Daiichi Sankyo head to FDA with ADC for small cell lung cancernews2025-09-07T21:31:10+00:00September 7th, 2025|Endpoints News|
#WCLC25: Summit reports full Phase 3 data from first group of Western lung cancer patientsnews2025-09-07T07:30:43+00:00September 7th, 2025|Endpoints News|
Regenxbio trumpets one-year data for Hunter syndrome gene therapy after FDA extended its reviewnews2025-09-05T14:14:19+00:00September 5th, 2025|Endpoints News|
BioNTech and DualityBio’s ADC hits in late-stage breast cancer trial in Chinanews2025-09-05T11:04:34+00:00September 5th, 2025|Endpoints News|
MindMed details Phase 2b LSD data in medical journalnews2025-09-04T15:00:19+00:00September 4th, 2025|Endpoints News|
AC Immune culls pipeline, lays off 30% of staff to extend cash runwaynews2025-09-04T14:07:31+00:00September 4th, 2025|Endpoints News|
FDA delays decision on Agios drug in thalassemia over liver safetynews2025-09-04T13:48:24+00:00September 4th, 2025|Endpoints News|
Sanofi’s stock takes a hit from subpar Phase 3 eczema datanews2025-09-04T11:26:52+00:00September 4th, 2025|Endpoints News|
Immunovant shares ‘unusual finding’ with first-gen FcRn drug in Graves’ diseasenews2025-09-04T10:58:35+00:00September 4th, 2025|Endpoints News|
Amgen, Zai Lab say stomach cancer drug’s survival benefit wanednews2025-09-03T20:17:45+00:00September 3rd, 2025|Endpoints News|
